In their study, Tsui et al. 2012 revealed that Luteolin at the concentration of 30 μM was effective against human prostate carcinoma LNCaP cells via promoting apoptosis, upregulating prostate-derived Ets factor (PDEF), and downregulating the androgen receptor (AR) expression [80]. Here, SPDEF is linked to prostate carcinoma.